|
End-of-day quote
Shenzhen S.E.
2026-03-12
|
5-day change
|
1st Jan Change
|
|
55.81 CNY
|
-1.31%
|
 |
-0.45%
|
-1.57%
|
|
Mar. 03 |
Frontage Laboratories, Inc. acquired Teddy Clinical Research Laboratory Co., Ltd from Hangzhou Tigermed Consulting Co., Ltd and Jiaxing Xinge Medical Consulting Co., Ltd.
|
CI
| |
Mar. 03 |
Frontage Unit Acquires Research Lab Firm from Tigermed Consulting Unit
|
MT
| |
Feb. 13 |
Beijing Trimmune Biotech Co., Ltd. announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd
|
CI
| |
Jan. 29 |
Tigermed Consulting Forecasts Upto 204% Jump in 2025 Profit; Shares Rise 8%
|
MT
| |
Jan. 29 |
Hangzhou Tigermed Consulting sees 2025 net profit up 105-204% Y/Y
|
RE
| |
Jan. 29 |
Tigermed Consulting Expects Up to 204% Surge in 2025 Profit
|
MT
| |
Nov. 25 |
HKEX says JP Morgan's long position in Hangzhou Tigermed Consulting H-shares increased to 7.71%
|
RE
| |
25-10-28 |
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
25-10-28 |
Tigermed Consulting's Q3 Profit Soars 99%
|
MT
| |
25-10-28 |
Hangzhou Tigermed Consulting posts qtrly revenue RMB1.78 billion
|
RE
| |
25-10-10 |
Hangzhou Tigermed Consulting to Sell Research Lab Firm to Frontage Unit
|
MT
| |
25-10-10 |
Hangzhou Tigermed Consulting announces disposal of Teddy Clinical Research Laboratory (Shanghai)
|
RE
| |
25-08-29 |
Hangzhou Tigermed Consulting's Attributable Profit Slides 22% in H1
|
MT
| |
25-08-28 |
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25-07-29 |
Tigermed completes acquisition of Japanese CRO Micron
|
RE
| |
25-07-29 |
Tigermed completes acquisition of Japanese CRO Micron
|
RE
| |
25-07-28 |
Hangzhou Tigermed Consulting says acquisition of partial equity interest in Micron in Japan by unit
|
RE
| |
25-07-18 |
Hangzhou Tigermed Consulting Sells 3.4% Stake in LaNova Medicines for $34 Million
|
MT
| |
25-07-17 |
Hangzhou Tigermed Consulting plans to sell stake in LaNova Medicines
|
RE
| |
25-07-05 |
Jiangsu Kangrun Biotechnology Co., Ltd. announced that it has received funding from BioTrack Capital, Hankang Capital, Green Pine Capital Partners Co., Ltd., Hangzhou Tigermed Consulting Co., Ltd, Hangzhou Luka Asset Management Co., Ltd., Shanghai Guanyou Investment and Development Co., Ltd.
|
CI
| |
25-05-30 |
Hangzhou Tigermed Consulting Co., Ltd Declares Final Dividend for the Year Ended December 31, 2024, Payable on 11 July 2025
|
CI
| |
25-04-30 |
Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024.
|
CI
| |
25-04-29 |
Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback announced on May 24, 2024, has closed with 9,806,300 shares, representing 1.14% for CNY 500.12 million.
|
CI
| |
25-04-28 |
Tigermed Consulting's Q1 Profit Slides 30%
|
MT
| |
25-04-28 |
Hangzhou Tigermed's Q1 Net Profit Down 29.6% Y/Y
|
RE
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
